STERIS is set to report its second-quarter results next month, and analysts are projecting a double-digit rise in earnings.

Steris (STE) stock and Solventum (SOLV) stock is upgraded, while RxSight (RXST) stock is downgraded at Morgan Stanley on valuations. Read more here.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $265.8, along ...

STE rides on strong Healthcare and AST growth, but macro pressures and customer consolidation cloud its outlook.

The medical device cleaning market is witnessing steady growth, driven by the increasing volume of surgical procedures and heightened awareness of infection control. Rising demand for sterilization ...

Bacterial spores can survive for long periods without nutrients and in harsh environmental conditions. This survival is influenced by the structure of the spore, the presence of protective compounds, ...

This paper presents a methodology for an autoclave sterilization process stages estimation using logistic regression models. The Autoclave sterilization process has four stages Pre-Vacuum, Rising ...

Steris acquired two Coon Rapids medical office buildings for $13.1M, expanding its Twin Cities footprint.